

Innovations from BrightEdge's **16 portfolio** companies have the **potential to positively impact 3.5M+ patients** and their families per year in the fight against cancer.


BY THE NUMBERS:

ACS Impact Venture Fund (AIVF)



3 NEW AIVF investments and **6 follow-on investments**, representing a

43% INCREASE in assets deployed



\$3.3B RAISED

by portfolio companies to advance **patient-centric innovations** such as therapeutics, diagnostics, devices, and other technologies



DRIVING IMPACT AND INNOVATION:



Partnering with ACS* Discovery Research to

narrow the gap between scientific grantmaking and equity investments.



Identifying and enabling the next generation of

cancer-fighting entrepreneurs and leaders.



Accelerating and amplifying the impact of

investments through thought leadership. In 2023, BrightEdge engaged over 330 participants at industry events focused on cancer impact and innovation.

BrightEdge, LLC is the American Cancer Society's innovation and impact investing arm. Visit acsbrightedge.org to learn more and view our 2023 Annual Report.

*The American Cancer Society is a leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. Visit cancer.org to learn more.